<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2905222079
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Fenido
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PIRFENIDONE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        267
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        90
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2170.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MSN LABORATORIES PRIVATE LIMITED " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MSN LABORATORIES PRIVATE LIMITED 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2096]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AX05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Fenido contains the active substance pirfenidone and it is used for the treatment of mild to moderate Idiopathic Pulmonary Fibrosis (IPF) in adults.</p><p>IPF is a condition in which the tissues in your lungs become swollen and scarred over time, and as a result makes it difficult to breathe deeply. This makes it hard for your lungs to work properly. Fenido helps to reduce scarring and swelling in the lungs, and helps you breathe better.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp; Do not take Fenido</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to pirfenidone or any of the other ingredients of this medicine (listed in section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have previously experienced angioedema with pirfenidone, including symptoms such as swelling of the face, lips and/or tongue which may be associated with difficulty breathing or wheezing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking a medicine called fluvoxamine (used to treat depression and obsessive compulsive disorder [OCD])</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe or end stage liver disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe or end stage kidney disease requiring dialysis.</p><p>If any of the above affects you, do not take Fenido. If you are unsure ask your doctor or pharmacist.</p><p>Warnings and precautions</p><p>Talk to your doctor or pharmacist before taking Fenido</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may become more sensitive to sunlight (photosensitivity reaction) when taking Fenido. Avoid the sun (including sunlamps) whilst taking Fenido. Wear sunblock daily and cover your arms, legs and head to reduce exposure to sunlight (see section 4: Possible side effects).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should not take other medicines, such as tetracycline antibiotics (such as doxycycline), which may make you more sensitive to sunlight.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should tell your doctor if you suffer from kidney problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should tell your doctor if you suffer from mild to moderate liver problems.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should stop smoking before and during treatment with Fenido. Cigarette smoking can reduce the effect of Fenido.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fenido may cause dizziness and tiredness. Be careful if you have to take part in activities where you have to be alert and co-ordinated.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fenido can cause weight loss. Your doctor will monitor your weight whilst you are taking this medicine.</p><p>You will need a blood test before you start taking Fenido and at monthly intervals for the first 6 months and then every 3 months thereafter whilst you are taking this medicine to check whether your liver is working properly. It is important that you have these regular blood tests for as long as you are taking Fenido.</p><p>Children and adolescents</p><p>Do not give Fenido to children and adolescents under the age of 18.</p><p>Other medicines and Fenido</p><p>Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.</p><p>This is especially important if you are taking the following medicines, as they may change the effect of Fenido.</p><p>Medicines that may increase side effects of Fenido:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; enoxacin (a type of antibiotic)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ciprofloxacin (a type of antibiotic)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; amiodarone (used to treat some types of heart disease)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; propafenone (used to treat some types of heart disease)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fluvoxamine (used to treat depression and obsessive compulsive disorder (OCD)).</p><p>Medicines that may reduce how well Fenido works:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; omeprazole (used in the treatment of conditions such as indigestion, gastroesophageal reflux disease)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin (a type of antibiotic).</p><p>Fenido with food and drink</p><p>Do not drink grapefruit juice whilst taking this medicine. Grapefruit may prevent Fenido from working properly.</p><p>Pregnancy and breast-feeding</p><p>As a precautionary measure, it is preferable to avoid the use of Fenido if you are pregnant, planning to become pregnant, or think you might be pregnant as the potential risks to the unborn child are unknown.</p><p>If you are breast-feeding or plan to breast-feed speak to your doctor or pharmacist before taking Fenido. As it is unknown whether Pirfenidone passes into breast milk, your doctor will discuss the risks and benefits of taking this medicine while breast-feeding if you decide to do so.</p><p>Driving and using machines</p><p>Do not drive or use machines if you feel dizzy or tired after taking Fenido.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Treatment with Fenido should be started and overseen by a specialist doctor experienced in the diagnosis and treatment of IPF.</p><p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Your medicine will usually be given to you in increasing doses as follows:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for the first 7 days take a dose of 267 mg (1 tablet), 3 times a day with food (a total of 801 mg/day)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; from day 8 to 14 take a dose of 534 mg (2 tablets of 267 mg), 3 times a day with food (a total of 1,602 mg/day)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; from day 15 onwards (maintenance), take a dose of 801 mg (3 tablets of 267 mg or 1 tablet of 801 mg), 3 times a day with food (a total of 2,403 mg/day).</p><p>The recommended maintenance daily dose of Fenido is 801 mg (3 tablets of 267 mg or 1 tablet of 801 mg) three times a day with food, for a total of 2403 mg/day.</p><p>Swallow the tablets whole with a drink of water, during or after a meal to reduce the risk of side effects such as nausea (feeling sick) and dizziness. If symptoms continue, see your doctor.</p><p><u>Dose reduction due to side effects</u></p><p>Your doctor may reduce your dose if you suffer from side effects such as, stomach problems, any skin reactions to sunlight or sun lamps, or significant changes to your liver enzymes.</p><p>If you take more Fenido than you should</p><p>Contact your doctor, pharmacist or nearest hospital casualty department immediately if you have taken more tablets than you should, and take your medicine with you.</p><p>If you forget to take Fenido</p><p>If you forget a dose, take it as soon as you remember. Do not take a double dose to make up for a forgotten dose. Each dose should be separated by at least 3 hours. Do not take more tablets each day than your prescribed daily dose.</p><p>If you stop taking Fenido</p><p>In some situations, your doctor may advise you to stop taking Fenido. If for any reason you have to stop taking Fenido for more than 14 consecutive days, your doctor will restart your treatment with a dose of 267 mg 3 times a day, gradually increasing this to a dose of 801 mg 3 times a day.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Stop taking Fenido and tell your doctor immediately</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you experience swelling of the face, lips and/or tongue, itching, hives, difficulty breathing or wheezing, or feeling faint, which are signs of angioedema, a serious allergic reaction or anaphylaxis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you experience yellowing of the eyes or skin, or dark urine, potentially accompanied by itching of the skin, which are signs of abnormal liver function tests. These are rare side effects.</p><p>Other side effects include</p><p>Talk to your doctor if you get any side effects.</p><p><strong>Very common side effects </strong>(may affect more than 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin reactions after going out in the sun or using sunlamps</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; indigestion or stomach upset</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache.</p><p><strong>Common side effects </strong>(may affect up to 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infections of the throat or the airways going into the lungs and/or sinusitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bladder infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight loss</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty sleeping</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sleepy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in taste</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hot flushes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach problems such as acid reflux, vomiting, feeling bloated, abdominal pain and discomfort, heart burn, feeling constipated and passing wind</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood tests may show increased levels of liver enzymes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin problems such as itchy skin, skin redness or red skin, dry skin, skin rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain, aching joints/joint pains</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling weak or feeling low in energy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sunburn.</p><p><strong>Rare side effects </strong>(may affect up to 1 in 1,000 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood tests may show decrease in white blood cells.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the blister and carton after EXP. The expiry date refers to the last day of that month.</p><p>Do not store above 30&deg;C</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is pirfenidone.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Fenido 267</u>: Each film-coated tablet contains 267 mg of pirfenidone.</p><p>The other ingredients are microcrystalline cellulose, croscarmellose sodium, hydroxypropyl cellulose, colloidal silicon dioxide and magnesium stearate.</p><p>The film coat of the tablet contains polyvinyl alcohol, titanium dioxide, Macrogol and talc.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Fenido 801</u>: Each film-coated tablet contains 801 mg of pirfenidone.</p><p>The other ingredients are microcrystalline cellulose, croscarmellose sodium, hydroxypropyl cellulose, colloidal silicon dioxide and magnesium stearate.</p><p>The film coat of the tablet contains polyvinyl alcohol, titanium dioxide, Macrogol and talc.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Fenido 267 (Pirfenidone Tablets 267 mg): White coloured, oval shaped, film coated tablets debossed with “M” on one side and “PF1” on other side, free from physical defects. Fenido 801 (Pirfenidone Tablets 801 mg): White coloured, oval shaped, film coated tablets debossed with “M” on one side and “PF3” on other side, free from physical defects.
Fenido tablets are packed in PVC/Aclar Blister pack.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tadawi Biomedical Company, Tadawi Biomedical-KSA Riyadh, Sudair Industrial Area, Zone A, Road 11, Factory 107, Saudi Arabia</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                07/2021

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">یحتوي <strong>فينيدو</strong> على المادة الفعالة بیرفینیدون وھو یسُتخدم لمعالجة التلیف الرئوي الخفیف إلى المتوسط مجھول السبب (IPF) لدى البالغین.</p><p dir="RTL">(IPF) ھي حالة تتورم فیھا أنسجة رئتیك وتتندب بمرور الوقت، ونتيجة لذلك تجعل التنفس بعمق أمراً صعباً. ھذا یجعل من الصعب على رئتیك العمل بشكل صحیح. یسُاعد <strong>فينيدو</strong> على تقلیل التندب ُّ والتورم في الرئتین، مما یسُاعدك على التنفس بشكل أفضل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تأخذ فينيدو&nbsp; </strong></p><p dir="RTL">&bull;&nbsp;&nbsp; إذا كنت تتحسس من بیرفینیدون أو أي من المكونات الأخرى لھذا الدواء (المدرجة في القسم 6).</p><p dir="RTL">&bull;&nbsp;&nbsp; إذا سبق لك أن عانیت من وذمة وعائیة مع بیرفینیدون، بما في ذلك أعراض مثل ُّ تورم الوجه، الشفتین و/أو اللسان الذي قد یترافق مع صعوبة في التنفس أو أزیز.</p><p dir="RTL">&bull;&nbsp;&nbsp; إذا كنت تتناول دواء یسُمى فلوفوكسامین (یسُتخدم لمعالجة الاكتئاب واضطراب الوسواس القھري</p><p>&nbsp; . OCD</p><p dir="RTL">&bull;&nbsp;&nbsp; إذا كان لدیك مرض كبدي حاد أو في مراحله النھائیة.</p><p dir="RTL">&bull;&nbsp;&nbsp; إذا كان لدیك مرض كلوي حاد أو في مراحله النھائیة یتطلب غسیل الكلى.</p><p dir="RTL">إذا تأثرت من أي مما سبق، لا تأخذ <strong>فينيدو</strong>.&nbsp; إذا كنت غیر متأكد، اسأل طبیبك أو الصیدلي.</p><p dir="RTL"><strong>المحاذیر والإحتیاطات&nbsp; </strong></p><p dir="RTL">تحدث إلى طبیبك أو الصیدلي قبل أخذ <strong>فينيدو </strong>&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp; قد تصبح أكثر حساسیة لأشعة الشمس (تفاعل الحساسیة للضوء) عند أخذ <strong>فينيدو</strong>. تجنب الشمس (بما في ذلك المصابیح الشمسیة) أثناء تناول <strong>فينيدو</strong>. ضع واقیا ً شمسیاً كل یوم وقم بتغطیة ذراعیك, ساقیك ورأسك لتقلیل التعرض لأشعة الشمس (انظر القسم 4: تأثیرات جانبیة محتملة) .</p><p dir="RTL">&bull;&nbsp;&nbsp; یجب علیك ألا تأخذ أدویة أخرى، مثل مضادات التتراسایكلین الحیویة (مثل دوكسیسایكلین)، التي قد تجعلك أكثر حساسیة لأشعة الشمس.</p><p dir="RTL">&bull;&nbsp;&nbsp; یجب أن تخبر طبیبك إذا كنت تعاني من مشاكل في الكلى.</p><p dir="RTL">&bull;&nbsp;&nbsp; یجب أن تخبر طبیبك إذا كنت تعاني من مشاكل خفیفة إلى متوسطة في الكبد.</p><p dir="RTL">&bull;&nbsp;&nbsp; یجب التوقف عن التدخین قبل وأثناء المعالجة بدواء <strong>فينيدو</strong>. قد یقلل تدخین السجائر من تأثیر <strong>فينيدو.</strong></p><p dir="RTL">&bull;&nbsp;&nbsp; قد یسبب <strong>فينيدو</strong> دوخة وتعب. كن حذراً إذا كنت تشارك&nbsp;&nbsp; بنشاطات تقتضي منك أن تكون متیقظاً ومتوازناً.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp; یمكن أن یسبب <strong>فينيدو </strong>فقدان الوزن. سیراقب طبیبك وزنك أثناء تناول ھذا الدواء.</p><p dir="RTL">ستحتاج إلى فحص دم قبل البدء بأخذ <strong>فينيدو</strong> وعلى فترات شھریة لمدة 6 أشھر الأولى ثم بعد ذلك كل 3 أشھر أثناء أخذ ھذا الدواء للتحقق فیما إذا كان كبدك یعمل بشكل صحیح.&nbsp; من المھم خضوعك لاختبارات الدم بانتظام طالما أنك تأخذ <strong>فينيدو</strong>.&nbsp;</p><p dir="RTL"><strong>الأطفال والمراھقون </strong></p><p dir="RTL">لا تعُطي <strong>فينيدو </strong>للأطفال والمراھقین دون 18 سنة من العمر.</p><p dir="RTL"><strong>أدویة أخرى وفينيدو&nbsp; </strong></p><p dir="RTL">أخبر طبیبك أو الصیدلي إذا كنت تأخذ، أو قد أخذت مؤخراً، أو قد تأخذ أیة أدویة أخرى.</p><p dir="RTL">ھذا مھم بشكل خاص إذا كنت تأخذ الأدویة التالیة، لأنھا قد تغیر من تأثیر <strong>فينيدو</strong>.</p><p dir="RTL">الأدویة التي قد <strong>تزید</strong> من التأثیرات الجانبیة لدواء <strong>فينيدو</strong>:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp; إینوكساسین (نوع من المضادات الحیویة)</p><p dir="RTL">&bull;&nbsp;&nbsp; سیبروفلوكساسین (نوع من المضادات الحیویة)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp; أمیودارون (سُتخدم لمعالجة بعض أنواع أمراض القلب)</p><p dir="RTL">&bull;&nbsp;&nbsp; بروبافینون (یسُتخدم لمعالجة بعض أنواع أمراض القلب)</p><p dir="RTL">&bull;&nbsp;&nbsp; فلوفوكسامین (یسُتخدم لمعالجة الاكتئاب واضطراب الوسواس القھري OCD).</p><p dir="RTL">الأدویة التي قد <strong>تقلل</strong> من جودة عمل <strong>فينيدو</strong>:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp; أومیبرازول (یسُتخدم في معالجة حالات مثل عسر الھضم, مرض الجزر المعدي المریئي)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp; ریفامبیسین (نوع من المضادات الحیویة.)</p><p dir="RTL"><strong>فينيدو مع الطعام والشراب </strong></p><p dir="RTL">لا تشرب عصیر الجریب فروت أثناء تناول ھذا الدواء. قد یمنع الجریب فروت من عمل <strong>فينيدو</strong> بشكل صحیح.</p><p dir="RTL"><strong>الحمل والرضاعة الطبیعیة </strong></p><p dir="RTL">كإجراء وقائي، من المفضل تجنب استخدام <strong>فينيدو </strong>إذا كنتِ حاملاً، أو تخُططین للحمل، أو تظنینَ أنكِ قد تكونینَ حاملاً لأن المخاطر المحتملة على الجنین غیر معروفة.</p><p dir="RTL">إذا كنتِ ترضعینَ رضاعة طبیعیة أو تخططینَ للإرضاع، تحدثي إلى طبیبك أو الصیدلي قبل أخذ <strong>فينيدو.</strong> نظراً لأنھ من غیر المعروف ما إذا كان بیرفینیدون ینتقل إلى حلیب الثدي، سوف یناقش طبیبكِ مخاطر وفوائد تناول ھذا الدواء أثناء الرضاعة الطبیعیة إذا قررتِ القیام بذلك.&nbsp;</p><p dir="RTL"><strong>القیادة واستخدام الآلات&nbsp; </strong></p><p dir="RTL">لا تقود السیارة أو تستخدم الآلات إذا شعرت بالدوار أو التعب بعد أخذ <strong>فينيدو.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">یجب أن تبدأ المعالجة بدواء <strong>فينيدو </strong>تحت إشراف طبیب متخصص ومن ذوي الخبرة في تشخیص ومعالجة IPF.</p><p dir="RTL">تناول ھذا الدواء دائماً كما أخبرك طبیبك والصیدلي تماماً. تحقق مع طبیبك أو الصیدلي إذا كنت غیر متأكد.</p><p dir="RTL">سوف یعُطى الدواء لك عادة على جرعات متزایدة على النحو التالي:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp; في الأیام الـ 7 الأولى، تناول جرعة من 267ملغ (قرص واحد) 3 مرات یومیاً مع الطعام (المجموع</p><p dir="RTL">801 ملغ/یوم.)</p><p dir="RTL">&bull;&nbsp;&nbsp; من الیوم الـ 8 إلى 14 تناول جرعة 534ملغ (قرصان 267ملغ) 3 مرات یومیاً مع الطعام (المجموع</p><p dir="RTL">1602ملغ/یوم.)</p><p dir="RTL">&bull;&nbsp;&nbsp; من الیوم الـ 15 فصاعداً (الاستمرار)، تناول جرعة 801ملغ (3 أقراص من 267ملغ أو قرص واحد من 801ملغ) 2 مرات يومياً مع الطعام (المجموع 2403ملغ/يوم).</p><p dir="RTL">جرعة الاستمرار الیومیة الموصى بھا من <strong>فينيدو</strong> ھي 801 ملغ (3 أقراص من 267ملغ أو قرص واحد من 801ملغ) 3 مرات في الیوم مع الطعام، المجموع 2403ملغ/یوم.&nbsp;</p><p dir="RTL">ابتلع الأقراص كاملة مع شرب الماء، أثناء أو بعد الوجبة لتقلیل مخاطر التأثیرات الجانبیة مثل الغثیان (الشعور بالغثیان) والدوخة. إذا استمرت الأعراض، راجع طبیبك.</p><p>تقلیل الجرعة بسبب التأثیرات الجانبیة</p><p dir="RTL">قد یقلل طبیبك جرعتك إذا عانیت من تأثیرات جانبیة مثل، مشاكل في المعدة، أیة تفاعلات جلدیة من أشعة الشمس أو مصابیح الشمس، أو تغییرات ملحوظة في إنزیمات الكبد.</p><p dir="RTL"><strong>إذا أخذت فينيدو أكثر مما یجب&nbsp; </strong></p><p dir="RTL">اتصل على الفور بطبیبك، الصیدلي أو قسم الحوادث لأقرب مستشفى إذا أخذت أقراصاً أكثر مما یجب، وخذ معك دواءك.</p><p dir="RTL"><strong>إذا نسیت تناول فينيدو&nbsp; </strong></p><p dir="RTL">إذا نسیت جرعة ما، خذھا حالما تتذكرھا. لا تأخذ جرعة مضاعفة لتعویض الجرعة المنسیة. یجب أن یكون الفاصل بین الجرعات مدة 3 ساعات على الأقل.&nbsp; لا تأخذ كل یوم أقراصاً أكثر من جرعتك الموصوفة لك یومیاً.&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول فينيدو&nbsp; </strong></p><p dir="RTL">في بعض الحالات، قد ینصحك طبیبك بالتوقف عن تناول <strong>فينيدو</strong>. فإذا اضطررت لأي سبب كان للتوقف عن تناول <strong>فينيدو</strong> لأكثر من 14 یوماً متتالیة، سیقوم طبیبك بإعادة معالجتك بجرعة من 267ملغ 3 مرات في الیوم، ثم یزیدھا تدریجیاً إلى جرعة 801ملغ 3 مرات في الیوم.</p><p dir="RTL">إذا كان لدیك أیة أسئلة أخرى حول استخدام ھذا الدواء، اسأل طبیبك أو الصیدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جمیع الأدویة، یمكن أن یسبب ھذا الدواء تأثیرات جانبیة، وإن كانت لا تحدث لكل شخص.</p><p dir="RTL">توقف عن تناول <strong>فينيدو </strong>وأخبر طبیبك في الحال&nbsp;</p><p dir="RTL">&bull;&nbsp; إذا عانیت من تورم في الوجه، الشفتین و/أو اللسان، حكة، شرى، صعوبة في التنفس أو أزیز، أو شعور بالإغماء، والتي ھي علامات على وذمة وعائیة، رد فعل تحسسي خطیر أو تأق.</p><p dir="RTL">&bull;&nbsp; إذا عانیت من اصفرار العینین أو الجلد، أو بول داكن، یحُتمل أن یكون مصحوباً بحكة في الجلد، والتي ھي علامات على اختبارات غیر طبیعیة لوظائف الكبد. وھذه تأثیرات جانبیة نادرة.</p><p dir="RTL"><strong>تأثیرات جانبیة أخرى تشمل: </strong></p><p dir="RTL">تحدث إلى طبیبك إذا حدث معك أیة تأثیرات جانبیة.</p><p dir="RTL"><strong>تأثیرات جانبیة شائعة جدا ً</strong> (قد تؤثر في 1 من كل 10 أشخاص):</p><p dir="RTL">&bull;&nbsp; ردود فعل جلدیة بعد الخروج في الشمس أو استخدام المصابیح الشمسية.</p><p dir="RTL">&bull;&nbsp; شعور بالغثیان (غثیان)</p><p dir="RTL">&bull;&nbsp; تعب</p><p dir="RTL">&bull;&nbsp; إسھال&nbsp;</p><p dir="RTL">&bull;&nbsp; عسر ھضم أو اضطراب المعدة</p><p dir="RTL">&bull;&nbsp; فقدان الشھیة</p><p dir="RTL">&bull;&nbsp; صداع</p><p dir="RTL"><strong>تأثیرات جانبیة شائعة</strong> (قد تؤثر حتى في 1 من كل 10 أشخاص):</p><p dir="RTL">&bull;&nbsp; التھابات الحلق أو المجاري الھوائیة الداخل ة للرئتین و/أو التھاب الجیوب الأنفیة&nbsp;</p><p dir="RTL">&bull;&nbsp; التھابات المثانة&nbsp;</p><p dir="RTL">&bull;&nbsp; فقدان الوزن&nbsp;</p><p dir="RTL">&bull;&nbsp; صعوبة النوم</p><p dir="RTL">&bull;&nbsp; دوخة&nbsp;</p><p dir="RTL">&bull;&nbsp; شعور بالنعاس&nbsp;</p><p dir="RTL">&bull;&nbsp; تغیرات في التذوق</p><p dir="RTL">&bull;&nbsp; ھبات ساخنة</p><p dir="RTL">&bull;&nbsp; ضیق في التنفس&nbsp;</p><p dir="RTL">&bull;&nbsp; سعال</p><p dir="RTL">&bull;&nbsp; مشاكل في المعدة مثل ارتجاع المريء، إقیاء، شعور بالانتفاخ، ألم في البطن وشعور بعدم الراحة، حرقان في القلب، شعور بالإمساك وإخراج ریح&nbsp;</p><p dir="RTL">&bull;&nbsp; قد تظُھر اختبارات الدم زیادة مستویات إنزیمات الكبد&nbsp;</p><p dir="RTL">&bull;&nbsp; مش اكل جلدیة مثل حكة الجلد، احمرار الجلد أو جلد أحمر، جفاف الجلد، طفح جلدي</p><p dir="RTL">&bull;&nbsp; آلام العضلات، مفاصل مؤلمة/ آلام مفصلیة&nbsp;</p><p dir="RTL">&bull;&nbsp; شعور بالضعف أو بانخفاض الطاقة&nbsp;</p><p dir="RTL">&bull;&nbsp; ألم صدر&nbsp;</p><p dir="RTL">&bull;&nbsp; ضربة شمس.</p><p dir="RTL"><strong>تأثیرات جانبیة نادرة</strong> (قد تؤثر حتى في 1 من كل 1000 شخص):</p><p dir="RTL">&bull;&nbsp; قد تظُھر اختبارات الدم انخفاضا ً في خلایا الدم البیضاء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ ھذا الدواء بعیداً عن رؤیة ومتناول أیدي الأطفال.</p><p dir="RTL">لا تستخدم ھذا الدواء بعد تاریخ انتھاء الصلاحیة المذكور على العبوة البلستر والعلبة بعد EXP. یشیر تاریخ انتھاء الصلاحیة إلى الیوم الأخیر من نفس الشھر.</p><p dir="RTL">لا یجوز تخزینه فوق 30 درجة مئویة&nbsp;</p><p dir="RTL">لا تتخلص من أیة أدویة عن طریق میاه الصرف الصحي أو النفایات المنزلیة. اسأل الصیدلي عن كیفیة التخلص من الأدویة التي لم تعد تستخدمھا. ھذه التدابیر سوف تساعد على حمایة البیئة.<strong> </strong></p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull;&nbsp; المادة الفعالة ھي بیرفینیدون.</p><p dir="RTL">&bull;&nbsp; <strong><u>فينيدو:</u></strong> یحتوي كل قرص مغلف بفلم 267 ملغ بیرفینیدون. المكونات الأخرى ھي</p><p dir="RTL">مایكروكریستالین سلیلوز، كروسكارمیلوز الصودیوم، ھایدروكسي بروبیلسلیلوز، ثاني أكسید السیلیكون الغرواني, وستیآرات المغنیسیوم.</p><p dir="RTL">یحتوي فلم تغلیف القرص على كحول بولي فینیلي، ثاني أكسید التیتانیوم، ماكروغول، وتلك.</p><p dir="RTL">&bull;&nbsp; <strong><u>فينيدو:</u></strong> یحتوي كل قرص مغلف بفلم على 801ملغ بیرفینیدون. المكونات الأخرى ھي</p><p dir="RTL">مایكروكریستالین سلیلوز, كروسك ارمیلوز الصودیوم، ھایدروكسي بروبیل&nbsp; سلیلوز، ثاني أكسید السیلیكون الغرواني, وستیآرات المغنیسیوم.</p><p dir="RTL">یحتوي فلم تغلیف القرص على كحول بولي فینیلي، ثاني أكسید التيتانيوم، ماكروغول، وتلك.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong><u>فينيدو </u></strong><u>(أقراص بیرفینیدون 267ملغ):</u> أقراص مغلفة بفلم، بلون أبيض، بیضاویة&nbsp;&nbsp; الشكل، منقوشة بالحرف&quot; M&quot; في جانب واحد و &quot;PF1&quot; في الجانب الآخر. خالیة من العیوب في الشكل.</p><p dir="RTL"><strong><u>فينيدو (أقراص</u></strong><u> بیرفینیدون 801ملغ)</u><u>:</u><u> </u>أقراص مغلفة بفلم، بلون أبیض، بیضاویة الشكل، منقوشة بالحرف&quot; M&quot; في جانب واحد و&quot; PF3&quot; في الجانب الآخر، خالیة من العیوب في الشكل.</p><p dir="RTL">أقراص <strong>فينيدو</strong> معبأة ضمن عبوة بلیستر PVC/Aclar.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>تداوي الحيوية الطبية&nbsp;</p><p dir="RTL">منطقة سدير الصناعية، سدير، المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            07/2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Fenido 267 (Pirfenidone Tablets 267 mg)
Fenido 801 (Pirfenidone Tablets 801 mg)

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Fenido 267 (Pirfenidone Tablets 267 mg): Each film-coated tablet contains 267 mg of pirfenidone.
Fenido 801 (Pirfenidone Tablets 801 mg): Each film-coated tablet contains 801 mg of pirfenidone.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet
Fenido 267 (Pirfenidone Tablets 267 mg): White coloured, oval shaped, film coated tablets debossed with “M” on one side and “PF1” on other side, free from physical defects.
Fenido 801 (Pirfenidone Tablets 801 mg): White coloured, oval shaped, film coated tablets debossed with “M” on one side and “PF3” on other side, free from physical defects.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fenido is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with Fenido should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of IPF.</p><p>Posology</p><p><em><u>Adults</u></em></p><p>Upon initiating treatment, the dose should be titrated to the recommended daily dose of 2403 mg/day over a 14-day period as follows:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Days 1 to 7: a dose of 267 mg administered three times a day (801 mg/day)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Days 8 to 14: a dose of 534 mg (two tablets of 267 mg) administered three times a day (1602 mg/day)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Day 15 onward: a dose of 801 mg administered three times a day (2403 mg/day)</p><p>The recommended maintenance daily dose of Fenido is 801 mg three times a day with food or a total of 2403 mg/day.</p><p>Doses above 2403 mg/day are not recommended for any patient (see section 4.9).</p><p>Patients who miss 14 consecutive days or more of Fenido treatment should re-initiate therapy by undergoing the initial 2-week titration regimen up to the recommended daily dose.</p><p>For treatment interruption of less than 14 consecutive days, the dose can be resumed at the previous recommended daily dose without titration.</p><p><em><u>Dose adjustments and other considerations for safe use</u></em></p><p><em>Gastrointestinal events: </em>In patients who experience intolerance to therapy due to gastrointestinal undesirable effects, patients should be reminded to take the medicinal product with food. If symptoms persist, the dose of pirfenidone may be reduced to 267 mg &ndash; 534 mg, two to three times a day with food with re-escalation to the recommended daily dose as tolerated. If symptoms continue, patients may be instructed to interrupt treatment for one to two weeks to allow symptoms to resolve.</p><p>&nbsp;</p><p><em>Photosensitivity reaction or rash: </em>Patients who experience a mild to moderate photosensitivity reaction or rash should be reminded to use a sunblock daily and avoid exposure to the sun (see section 4.4). The dose of pirfenidone may be reduced to 801 mg each day (267 mg three times a day). If the rash persists after 7 days, Fenido should be discontinued for 15 days, with re-escalation to the recommended daily dose in the same manner as the dose escalation period.</p><p>Patients who experience severe photosensitivity reaction or rash should be instructed to interrupt the dose and to seek medical advice (see section 4.4). Once the rash has resolved, Fenido may be re-introduced and re-escalated up to the recommended daily dose at the discretion of the physician.</p><p><em>Hepatic function: </em>In the event of significant elevation of alanine and/or aspartate aminotransferases (ALT/AST) with or without bilirubin elevation, the dose of pirfenidone should be adjusted or treatment discontinued according to the guidelines listed in section 4.4.</p><p><u>Special populations</u></p><p><em>Elderly</em></p><p>No dose adjustment is necessary in patients 65 years and older (see section 5.2).</p><p><em>Hepatic impairment</em></p><p>No dose adjustment is necessary in patients with mild to moderate hepatic impairment (i.e. Child-Pugh Class A and B). However, since plasma levels of pirfenidone may be increased in some individuals with mild to moderate hepatic impairment, caution should be used with Fenido treatment in this population. Fenido therapy should not be used in patients with severe hepatic impairment or end stage liver disease (see section 4.3, 4.4 and 5.2).</p><p><em>Renal impairment</em></p><p>No dose adjustment is necessary in patients with mild renal impairment. Fenido should be used with caution in patients with moderate (CrCl 30-50 ml/min) renal impairment. Fenido therapy should not be used in patients with severe renal impairment (CrCl &lt;30 ml/min) or end stage renal disease requiring dialysis (see sections 4.3 and 5.2).</p><p><em>Paediatric population</em></p><p>There is no relevant use of Fenido in the paediatric population for the indication of IPF.</p><p><u>Method of administration</u></p><p>Fenido is for oral use. The tablets are to be swallowed whole with water and taken with food to reduce the possibility of nausea and dizziness (see sections 4.8 and 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
•	History of angioedema with pirfenidone (see section 4.4)
•	Concomitant use of fluvoxamine (see section 4.5)
•	Severe hepatic impairment or end stage liver disease (see sections 4.2 and 4.4).
•	Severe renal impairment (CrCl <30 ml/min) or end stage renal disease requiring dialysis (see sections 4.2 and 5.2).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hepatic function</u></p><p>Elevations in ALT and AST &gt;3 &times; upper limit of normal (ULN) have been reported in patients receiving therapy with Pirfenidone. Rarely these have been associated with concomitant elevations in total serum bilirubin. Liver function tests (ALT, AST and bilirubin) should be conducted prior to the initiation of treatment with Fenido, and subsequently at monthly intervals for the first 6 months and then every 3 months thereafter (see section 4.8). In the event of significant elevation of liver aminotransferases the dose of Fenido should be adjusted or treatment discontinued according to the guidelines listed below. For patients with confirmed elevations in ALT, AST or bilirubin during treatment, the following dose adjustments may be necessary.</p><p>&nbsp;</p><p><u>Recommendations in case of ALT/AST elevations</u></p><p>If a patient exhibits an aminotransferase elevation to &gt;3 to &le;5 x ULN after starting Fenido therapy, confounding medicinal products should be discontinued, other causes excluded, and the patient monitored closely. If clinically appropriate the dose of Fenido should be reduced or interrupted. Once liver function tests are within normal limits Fenido may be re-escalated to the recommended daily dose if tolerated.</p><p>If a patient exhibits an aminotransferase elevation to &le;5 x ULN accompanied by symptoms or hyperbilirubinaemia, Fenido should be discontinued and the patient should not be rechallenged.</p><p>If a patient exhibits an aminotransferase elevation to &gt;5 x ULN, Fenido should be discontinued and the patient should not be rechallenged.</p><p><u>Hepatic impairment</u></p><p>In subjects with moderate hepatic impairment (i.e. Child-Pugh Class B), pirfenidone exposure was increased by 60%. Fenido should be used with caution in patients with pre-existing mild to moderate hepatic impairment (i.e. Child-Pugh Class A and B) given the potential for increased pirfenidone exposure. Patients should be monitored closely for signs of toxicity especially if they are concomitantly taking a known CYP1A2 inhibitor (see sections 4.5 and 5.2). Pirfenidone has not been studied in individuals with severe hepatic impairment and Pirfenidone must not be used in patients with severe hepatic impairment (see section 4.3).</p><p><u>Photosensitivity reaction and rash</u></p><p>Exposure to direct sunlight (including sunlamps) should be avoided or minimised during treatment with Fenido. Patients should be instructed to use a sunblock daily, to wear clothing that protects against sun exposure, and to avoid other medicinal products known to cause photosensitivity. Patients should be instructed to report symptoms of photosensitivity reaction or rash to their physician. Severe photosensitivity reactions are uncommon. Dose adjustments or temporary treatment discontinuation may be necessary in mild to severe cases of photosensitivity reaction or rash (see section 4.2).</p><p><u>Angioedema/Anaphylaxis</u></p><p>Reports of angioedema (some serious) such as swelling of the face, lips and/or tongue which may be associated with difficulty breathing or wheezing have been received in association with use of Pirfenidone in the post-marketing setting. Reports of anaphylactic reactions have also been received. Therefore, patients who develop signs or symptoms of angioedema or severe allergic reactions following administration of Pirfenidone should immediately discontinue treatment. Patients with angioedema or severe allergic reactions should be managed according to standard of care. Pirfenidone must not be used in patients with a history of angioedema or hypersensitivity due to Pirfenidone (see section 4.3).</p><p><u>Dizziness</u></p><p>Dizziness has been reported in patients taking Pirfenidone. Therefore, patients should know how they react to this medicinal product before they engage in activities requiring mental alertness or coordination (see section 4.7). In clinical studies, most patients who experienced dizziness had a single event, and most events resolved, with a median duration of 22 days. If dizziness does not improve or if it worsens in severity, dose adjustment or even discontinuation of Fenido may be warranted.</p><p><u>Fatigue</u></p><p>Fatigue has been reported in patients taking Pirfenidone. Therefore, patients should know how they react to this medicinal product before they engage in activities requiring mental alertness or coordination (see section 4.7).</p><p><u>Weight loss</u></p><p>Weight loss has been reported in patients treated with Pirfenidone (see section 4.8). Physicians should monitor patient&#39;s weight, and when appropriate encourage increased caloric intake if weight loss is considered to be of clinical significance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>1.1&nbsp;&nbsp;&nbsp; </strong>Approximately 70&ndash;80% of pirfenidone is metabolised via CYP1A2 with minor contributions from other CYP isoenzymes including CYP2C9, 2C19, 2D6, and 2E1.</p><p>Consumption of grapefruit juice is associated with inhibition of CYP1A2 and should be avoided during treatment with pirfenidone.</p><p><u>Fluvoxamine and inhibitors of CYP1A2</u></p><p>In a Phase 1 study, the co-administration of Pirfenidone and fluvoxamine (a strong inhibitor of CYP1A2 with inhibitory effects on other CYP isoenzymes [CYP2C9, 2C19, and 2D6]) resulted in a 4-fold increase in exposure to pirfenidone in non-smokers.</p><p>Fenido is contraindicated in patients with concomitant use of fluvoxamine (see section 4.3). Fluvoxamine should be discontinued prior to the initiation of Fenido therapy and avoided during Fenido therapy due to the reduced clearance of pirfenidone. Other therapies that are inhibitors of both CYP1A2 and one or more other CYP isoenzymes involved in the metabolism of pirfenidone (e.g. CYP2C9, 2C19, and 2D6) should be avoided during pirfenidone treatment.</p><p><em>In vitro </em>and <em>in vivo </em>extrapolations indicate that strong and selective inhibitors of CYP1A2 (e.g. enoxacin) have the potential to increase the exposure to pirfenidone by approximately 2 to 4-fold. If concomitant use of Pirfenidone with a strong and selective inhibitor of CYP1A2 cannot be avoided, the dose of pirfenidone should be reduced to 801 mg daily (267 mg, three times a day). Patients should be closely monitored for emergence of adverse reactions associated with Fenido therapy. Discontinue Fenido if necessary (see sections 4.2 and 4.4).</p><p>Co-administration of Pirfenidone and 750 mg of ciprofloxacin (a moderate inhibitor of CYP1A2) increased the exposure to pirfenidone by 81%. If ciprofloxacin at the dose of 750 mg two times a day cannot be avoided, the dose of pirfenidone should be reduced to 1602 mg daily (534 mg three times a day). Fenido should be used with caution when ciprofloxacin is used at a dose of 250 mg or 500 mg once or two times a day.</p><p>Fenido should be used with caution in patients treated with other moderate inhibitors of CYP1A2 (e.g. amiodarone, propafenone).</p><p>Special care should also be exercised if CYP1A2 inhibitors are being used concomitantly with potent inhibitors of one or more other CYP isoenzymes involved in the metabolism of pirfenidone such as CYP2C9 (e.g. amiodarone, fluconazole), 2C19 (e.g. chloramphenicol) and 2D6 (e.g. fluoxetine, paroxetine).</p><p><u>Cigarette smoking and inducers of CYP1A2</u></p><p>A Phase 1 interaction study evaluated the effect of cigarette smoking (CYP1A2 inducer) on the pharmacokinetics of pirfenidone. The exposure to pirfenidone in smokers was 50% of that observed in non-smokers. Smoking has the potential to induce hepatic enzyme production and thus increase medicinal product clearance and decrease exposure. Concomitant use of strong inducers of CYP1A2 including smoking should be avoided during Fenido therapy based on the observed relationship between cigarette smoking and its potential to induce CYP1A2. Patients should be encouraged to discontinue use of strong inducers of CYP1A2 and to stop smoking before and during treatment with pirfenidone.</p><p>In the case of moderate inducers of CYP1A2 (e.g. omeprazole), concomitant use may theoretically result in a lowering of pirfenidone plasma levels.</p><p>Co-administration of medicinal products that act as potent inducers of both CYP1A2 and the other CYP isoenzymes involved in the metabolism of pirfenidone (e.g. rifampicin) may result in significant lowering of pirfenidone plasma levels. These medicinal products should be avoided whenever possible.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no data from the use of Pirfenidone in pregnant women.</p><p>In animals placental transfer of pirfenidone and/or its metabolites occurs with the potential for accumulation of pirfenidone and/or its metabolites in amniotic fluid.</p><p>&nbsp;</p><p>At high doses (&ge;1,000 mg/kg/day) rats exhibited prolongation of gestation and reduction in foetal viability.</p><p>As a precautionary measure, it is preferable to avoid the use of Fenido during pregnancy. <u>Breast-feeding</u></p><p>It is unknown whether pirfenidone or its metabolites are excreted in human milk. Available</p><p>pharmacokinetic data in animals have shown excretion of pirfenidone and/or its metabolites in milk with the potential for accumulation of pirfenidone and/or its metabolites in milk (see section 5.3). A risk to the breastfed infant cannot be excluded.</p><p>A decision must be made whether to discontinue breast-feeding or to discontinue from Pirfenidone therapy, taking into account the benefit of breast-feeding for the child and the benefit of Pirfenidone therapy for the mother.</p><p><u>Fertility</u></p><p>No adverse effects on fertility were observed in preclinical studies (see section 5.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pirfenidone may cause dizziness and fatigue, which could have a moderate influence on the ability to drive or use machines, therefore patients should exercise caution when driving or operating machinery if they experience these symptoms.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Summary of the safety profile</u></em></p><p>The most frequently reported adverse reactions during clinical study experience with Pirfenidone at a dose of 2,403 mg/day compared to placebo, respectively, were nausea (32.4% versus 12.2%), rash (26.2% versus 7.7%), diarrhoea (18.8% versus 14.4%), fatigue (18.5%</p><p>versus 10.4%), dyspepsia (16.1% versus 5.0%), anorexia (11.4% versus 3.5%), headache</p><p>(10.1% versus 7.7%), and photosensitivity reaction (9.3% versus 1.1%).</p><p><em><u>Tabulated list of adverse reactions</u></em></p><p>The safety of Pirfenidone has been evaluated in clinical studies including 1,650 volunteers and patients. More than 170 patients have been investigated in open studies for more than five years and some for up to 10 years.</p><p>Table 1 shows the adverse reactions reported at a frequency of &ge;2% in 623 patients receiving Pirfenidone at the recommended dose of 2,403 mg/day in three pooled pivotal Phase 3 studies. Adverse reactions from post-marketing experience are also listed in Table 1. Adverse reactions are listed by System Organ Class (SOC) and within each frequency grouping [Very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to</p><p>&lt;1/1,000), not known (cannot be estimated from the available data)] the adverse reactions are presented in order of decreasing seriousness.</p><p>Table 1: Adverse reactions by SOC and MedDRA frequency</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Upper respiratory tract infection; urinary tract infection</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Agranulocytosis<sup>1</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Angioedema<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Anaphylaxis<sup>1</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Anorexia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Weight decreased; decreased appetite</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Insomnia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dizziness; somnolence; dysgeusia; lethargy</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hot flush</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dyspnoea; cough; productive cough</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal</strong><strong> </strong><strong>disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Dyspepsia; nausea; diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Gastroesophageal reflux disease; vomiting; abdominal distension; abdominal discomfort; abdominal pain; abdominal pain upper;</p><p>stomach discomfort; gastritis; constipation; flatulence</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>ALT&nbsp; increased;&nbsp; AST&nbsp; increased;&nbsp; gamma&nbsp; glutamyl&nbsp; transferase</p><p>increased</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Total serum bilirubin increased in combination with increases of ALT</p><p>and AST<sup>1</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Photosensitivity reaction; rash</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pruritus; erythema; dry skin; rash erythematous; rash macular; rash</p><p>pruritic</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Myalgia; arthralgia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Fatigue</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Asthenia; non-cardiac chest pain</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Injury poisoning and procedural complications</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Sunburn</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>1.&nbsp;&nbsp;&nbsp;&nbsp; Identified through post-marketing surveillance</p></td></tr></tbody></table><p><strong>To report any side effect(s):</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to the competent authority in Saudi Arabia as per details below:</p><p>&bull;&nbsp; <strong><u>Saudi Arabia</u></strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="docshape41" o:spid="_x0000_s1026" type="#_x0000_t202"
  style='position:absolute;margin-left:125.05pt;margin-top:4.65pt;width:371.55pt;
  height:100.3pt;z-index:-15709696;mso-wrap-distance-left:0;
  mso-wrap-distance-right:0;mso-position-horizontal-relative:page' filled="f"
  strokeweight="1pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:3.25pt;margin-right:0in;margin-bottom:
     0in;margin-left:7.1pt;margin-bottom:.0001pt'><span style='font-size:12.0pt;
     mso-bidi-font-size:11.0pt'>The<span style='letter-spacing:-.2pt'> </span>National<span
     style='letter-spacing:-.2pt'> </span>Pharmacovigilance<span
     style='letter-spacing:-.2pt'> </span>Centre<span style='letter-spacing:
     -.2pt'> (NPC)</span><o:p></o:p></span></p>
     <p class=MsoNormal style='margin-top:2.15pt;margin-right:0in;margin-bottom:
     0in;margin-left:25.1pt;margin-bottom:.0001pt;tab-stops:43.1pt'><span
     style='font-size:12.0pt;mso-bidi-font-size:11.0pt;letter-spacing:-.5pt'>-</span><span
     style='font-size:12.0pt;mso-bidi-font-size:11.0pt'><span style='mso-tab-count:
     1'>     </span>Fax:<span style='letter-spacing:-.35pt'> </span>+966-11-205-<span
     style='letter-spacing:-.2pt'>7662</span><o:p></o:p></span></p>
     <p class=MsoNormal style='margin-top:2.05pt;margin-right:0in;margin-bottom:
     0in;margin-left:25.1pt;margin-bottom:.0001pt;tab-stops:43.1pt'><span
     style='font-size:12.0pt;mso-bidi-font-size:11.0pt;letter-spacing:-.5pt'>-</span><span
     style='font-size:12.0pt;mso-bidi-font-size:11.0pt'><span style='mso-tab-count:
     1'>     </span>Call<span style='letter-spacing:-.2pt'> </span>NPC<span
     style='letter-spacing:-.15pt'> </span>at<span style='letter-spacing:-.15pt'>
     </span>+966-11-2038222,<span style='letter-spacing:-.1pt'> </span>Ext<span
     style='letter-spacing:-.15pt'> </span>2317-2356-<span style='letter-spacing:
     -.2pt'>2340</span><o:p></o:p></span></p>
     <p class=MsoNormal style='margin-top:2.05pt;margin-right:0in;margin-bottom:
     0in;margin-left:43.1pt;margin-bottom:.0001pt;text-indent:-18.05pt;
     mso-list:l0 level1 lfo2;tab-stops:43.1pt 43.15pt'><![if !supportLists]><span
     style='font-size:12.0pt;mso-font-width:99%'><span style='mso-list:Ignore'>-<span
     style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=LTR></span><span
     style='font-size:12.0pt;mso-bidi-font-size:11.0pt'>SFDA<span
     style='letter-spacing:-.3pt'> </span>Call<span style='letter-spacing:-.2pt'>
     </span>Centre:<span style='letter-spacing:-.25pt'> </span><span
     style='letter-spacing:-.2pt'>19999</span><o:p></o:p></span></p>
     <p class=MsoNormal style='margin-top:2.05pt;margin-right:0in;margin-bottom:
     0in;margin-left:43.1pt;margin-bottom:.0001pt;text-indent:-18.05pt;
     mso-list:l0 level1 lfo2;tab-stops:43.1pt 43.15pt'><![if !supportLists]><span
     style='font-size:12.0pt;mso-font-width:99%'><span style='mso-list:Ignore'>-<span
     style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=LTR></span><span
     style='font-size:12.0pt;mso-bidi-font-size:11.0pt'>E-mail:<span
     style='letter-spacing:-.55pt'> </span></span><a
     href="mailto:npc.drug@sfda.gov.sa"><span style='font-size:12.0pt;
     mso-bidi-font-size:11.0pt;color:#0563C2;letter-spacing:-.1pt;text-decoration:
     none;text-underline:none'>npc.drug@sfda.gov.sa</span></a><span
     style='font-size:12.0pt;mso-bidi-font-size:11.0pt'><o:p></o:p></span></p>
     <p class=MsoNormal style='margin-top:2.15pt;margin-right:0in;margin-bottom:
     0in;margin-left:43.1pt;margin-bottom:.0001pt;text-indent:-18.05pt;
     mso-list:l0 level1 lfo2;tab-stops:43.1pt 43.15pt'><![if !supportLists]><span
     style='font-size:12.0pt;mso-font-width:99%'><span style='mso-list:Ignore'>-<span
     style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=LTR></span><span
     style='font-size:12.0pt;mso-bidi-font-size:11.0pt'>Website:<span
     style='letter-spacing:-.35pt'> </span><span style='color:#0563C2;
     letter-spacing:-.1pt'>https://ade.sfda.gov.sa/</span><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>The National Pharmacovigilance Centre (NPC)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222, Ext 2317-2356-2340</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Centre: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p>&bull;&nbsp; <strong><u>Other GCC States:</u></strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is limited clinical experience with overdose. Multiple doses of pirfenidone up to a total dose of 4,806 mg/day were administered as six 267 mg capsules three times daily to healthy adult volunteers over a 12-day dose escalation period. Adverse reactions were mild, transient, and consistent with the most frequently reported adverse reactions for pirfenidone.</p><p>In the event of a suspected overdose, supportive medical care should be provided including monitoring of vital signs and close observation of the clinical status of the patient.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Immunosuppressants, other immunosuppressants, ATC code: L04AX05</p><p>&nbsp;</p><p>The mechanism of action of pirfenidone has not been fully established. However, existing data suggest that pirfenidone exerts both antifibrotic and anti-inflammatory properties in a variety of <em>in vitro </em>systems and animal models of pulmonary fibrosis (bleomycin- and transplant-induced fibrosis).</p><p>IPF is a chronic fibrotic and inflammatory pulmonary disease affected by the synthesis and release of pro-inflammatory cytokines including tumour necrosis factor-alpha (TNF-&alpha;) and interleukin-1-beta (IL-1&beta;) and pirfenidone has been shown to reduce the accumulation of inflammatory cells in response to various stimuli.</p><p>Pirfenidone attenuates fibroblast proliferation, production of fibrosis-associated proteins and cytokines, and the increased biosynthesis and accumulation of extracellular matrix in response to cytokine growth factors such as, transforming growth factor-beta (TGF-&beta;) and platelet-derived growth factor (PDGF).</p><p><u>Clinical efficacy</u></p><p>The clinical efficacy of Pirfenidone has been studied in four Phase 3, multicentre, randomised, double-blind, placebo-controlled studies in patients with IPF. Three of the Phase 3 studies (PIPF-004, PIPF-006, and PIPF-016) were multinational, and one (SP3) was conducted in Japan.</p><p>PIPF-004 and PIPF-006 compared treatment with Pirfenidone 2403 mg/day to placebo. The studies were nearly identical in design, with few exceptions including an intermediate dose group (1,197 mg/day) in PIPF-004. In both studies, treatment was administered three times daily for a minimum of 72 weeks. The primary endpoint in both studies was the change from Baseline to Week 72 in percent predicted Forced Vital Capacity (FVC).</p><p>In study PIPF-004, the decline of percent predicted FVC from Baseline at Week 72 of treatment was significantly reduced in patients receiving Pirfenidone (N=174) compared with patients receiving placebo (N=174; p=0.001, rank ANCOVA). Treatment with Pirfenidone also significantly reduced the decline of percent predicted FVC from Baseline at Weeks 24 (p=0.014), 36 (p&lt;0.001), 48 (p&lt;0.001), and 60 (p&lt;0.001). At Week 72, a decline from baseline in percent predicted FVC of &ge;10% (a threshold indicative of the risk of mortality in IPF) was seen in 20% of patients receiving Pirfenidone compared to 35% receiving placebo (Table 2)<em>.</em></p><p>Table 2: Categorical assessment of change from Baseline to Week 72 in percent predicted FVC in study PIPF-004</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Pirfenidone 2403 mg/day (N=174)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo (N=174)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Decline of &ge;10% or death or</p><p>lung transplant</p></td><td style="vertical-align:top"><p>35 (20%)</p></td><td style="vertical-align:top"><p>60 (34%)</p></td></tr><tr><td style="vertical-align:top"><p>Decline of less than 10%</p></td><td style="vertical-align:top"><p>97 (56%)</p></td><td style="vertical-align:top"><p>90 (52%)</p></td></tr><tr><td style="vertical-align:top"><p>No&nbsp; decline&nbsp; (FVC&nbsp; change</p><p>&gt;0%)</p></td><td style="vertical-align:top"><p>42 (24%)</p></td><td style="vertical-align:top"><p>24 (14%)</p></td></tr></tbody></table><p>Although there was no difference between patients receiving Pirfenidone compared to placebo in change from Baseline to Week 72 of distance walked during a six minute walk test (6MWT) by the prespecified rank ANCOVA, in an <em>ad hoc </em>analysis, 37% of patients receiving Pirfenidone showed a decline of &ge;50 m in 6MWT distance, compared to 47% of patients receiving placebo in PIPF-004.</p><p>In study PIPF-006, treatment with Pirfenidone (N=171) did not reduce the decline of percent predicted FVC from Baseline at Week 72 compared with placebo (N=173; p=0.501). However, treatment with Pirfenidone reduced the decline of percent predicted FVC from Baseline at Weeks 24 (p&lt;0.001), 36 (p=0.011), and 48 (p=0.005). At Week 72, a decline in FVC of &ge;10% was seen in 23% of patients receiving Pirfenidone and 27% receiving placebo (Table 3).</p><p>Table 3: Categorical assessment of change from Baseline to Week 72 in percent predicted FVC in study PIPF-006</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Pirfenidone 2403 mg/day (N=171)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo (N=173)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Decline of &ge;10% or death or lung</p><p>transplant</p></td><td style="vertical-align:top"><p>39 (23%)</p></td><td style="vertical-align:top"><p>46 (27%)</p></td></tr><tr><td style="vertical-align:top"><p>Decline of less than 10%</p></td><td style="vertical-align:top"><p>88 (52%)</p></td><td style="vertical-align:top"><p>89 (51%)</p></td></tr><tr><td style="vertical-align:top"><p>No decline (FVC change &gt;0%)</p></td><td style="vertical-align:top"><p>44 (26%)</p></td><td style="vertical-align:top"><p>38 (22%)</p></td></tr></tbody></table><p>&nbsp;</p><p>The decline in 6MWT distance from Baseline to Week 72 was significantly reduced compared with placebo in study PIPF-006 (p&lt;0.001, rank ANCOVA). Additionally, in an <em>ad hoc </em>analysis, 33% of patients receiving Pirfenidone showed a decline of &ge;50 m in 6MWT distance, compared to 47% of patients receiving placebo in PIPF-006.</p><p>In a pooled analysis of survival in PIPF-004 and PIPF-006 the mortality rate with Pirfenidone 2403 mg/day group was 7.8% compared with 9.8% with placebo (HR 0.77 [95% CI, 0.47&ndash;</p><p>1.28]).</p><p>PIPF-016 compared treatment with Pirfenidone 2,403 mg/day to placebo. Treatment was administered three times daily for 52 weeks. The primary endpoint was the change from Baseline to Week 52 in percent predicted FVC. In a total of 555 patients, the median baseline percent predicted FVC and %DLCO were 68% (range: 48&ndash;91%) and 42% (range: 27&ndash;170%), respectively. Two percent of patients had percent predicted FVC below 50% and 21% of patients had a percent predicted DLCO below 35% at Baseline.</p><p>In study PIPF-016, the decline of percent predicted FVC from Baseline at Week 52 of treatment was significantly reduced in patients receiving Pirfenidone (N=278) compared with patients receiving placebo (N=277; p&lt;0.000001, rank ANCOVA). Treatment with Pirfenidone also significantly reduced the decline of percent predicted FVC from Baseline at Weeks 13 (p&lt;0.000001), 26 (p&lt;0.000001), and 39 (p=0.000002). At Week 52, a decline from Baseline in percent predicted FVC of &ge;10% or death was seen in 17% of patients receiving Pirfenidone compared to 32% receiving placebo (Table 4).</p><p>Table 4: Categorical assessment of change from Baseline to Week 52 in percent predicted FVC in study PIPF-016</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Pirfenidone 2403 mg/day (N=278)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo (N=277)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Decline of &ge;10% or death</p></td><td style="vertical-align:top"><p>46 (17%)</p></td><td style="vertical-align:top"><p>88 (32%)</p></td></tr><tr><td style="vertical-align:top"><p>Decline of less than 10%</p></td><td style="vertical-align:top"><p>169 (61%)</p></td><td style="vertical-align:top"><p>162 (58%)</p></td></tr><tr><td style="vertical-align:top"><p>No&nbsp; decline&nbsp; (FVC&nbsp; change</p><p>&gt;0%)</p></td><td style="vertical-align:top"><p>63 (23%)</p></td><td style="vertical-align:top"><p>27 (10%)</p></td></tr></tbody></table><p>The decline in distance walked during a 6MWT from Baseline to Week 52 was significantly reduced in patients receiving Pirfenidone compared with patients receiving placebo in PIPF-016 (p=0.036, rank ANCOVA); 26% of patients receiving Pirfenidone showed a decline of &ge;50 m in 6MWT distance compared to 36% of patients receiving placebo.</p><p>In a pre-specified pooled analysis of studies PIPF-016, PIPF-004, and PIPF-006 at Month 12, all-cause mortality was significantly lower in Pirfenidone 2403 mg/day group (3.5%, 22 of 623 patients) compared with placebo (6.7%, 42 of 624 patients), resulting in a 48% reduction in the risk of all-cause mortality within the first 12 months (HR 0.52 [95% CI, 0.31&ndash;0.87], p=0.0107, log-rank test).</p><p>The study (SP3) in Japanese patients compared pirfenidone 1800 mg/day (comparable to 2403 mg/day in the US and European populations of PIPF-004/006 on a weight-normalised basis) with placebo (N=110, N=109, respectively). Treatment with pirfenidone significantly reduced mean decline in vital capacity (VC) at Week 52 (the primary endpoint) compared with placebo (-0.09&plusmn;0.02 l versus -0.16&plusmn;0.02 l respectively, p=0.042).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Administration of Pirfenidone capsules with food results in a large reduction in Cmax (by 50%) and a smaller effect on AUC, compared to the fasted state. Following oral administration of a single dose of 801 mg to healthy older adult volunteers (50-66 years of age) in the fed state, the rate of pirfenidone absorption slowed, while the AUC in the fed state was approximately 80-85% of the AUC observed in the fasted state. Bioequivalence was demonstrated in the fasted state when comparing the 801 mg tablet to three 267 mg capsules. In the fed state, the 801 mg tablet met bioequivalence criteria based on the AUC measurements compared to the capsules, while the 90% confidence intervals for Cmax (108.26% - 125.60%) slightly exceeded the upper bound of standard bioequivalence limit (90% CI: 80.00% - 125.00%). The effect of food on pirfenidone oral AUC was consistent between the tablet and capsule formulations. Compared to the fasted state, administration of either formulation with food reduced pirfenidone Cmax, with</p><p>&nbsp;</p><p>Pirfenidone tablet reducing the Cmax slightly less (by 40%) than Pirfenidone capsules (by 50%). A reduced incidence of adverse events (nausea and dizziness) was observed in fed subjects when compared to the fasted group. Therefore, it is recommended that Pirfenidone be administered with food to reduce the incidence of nausea and dizziness.</p><p>The absolute bioavailability of pirfenidone has not been determined in humans.</p><p><u>Distribution</u></p><p>Pirfenidone binds to human plasma proteins, primarily to serum albumin. The overall mean binding ranged from 50% to 58% at concentrations observed in clinical studies (1 to 100 &mu;g/ml). Mean apparent oral steady-state volume of distribution is approximately 70 l, indicating that pirfenidone distribution to tissues is modest.</p><p><u>Biotransformation</u></p><p>Approximately 70&ndash;80% of pirfenidone is metabolised via CYP1A2 with minor contributions from other CYP isoenzymes including CYP2C9, 2C19, 2D6, and 2E1. <em>In vitro </em>data indicate some pharmacologically relevant activity of the major metabolite (5-carboxy-pirfenidone) at concentrations in excess of peak plasma concentrations in IPF patients. This may become clinically relevant in patients with moderate renal impairment where plasma exposure to 5-carboxy-pirfenidone is increased.</p><p><u>Elimination</u></p><p>The oral clearance of pirfenidone appears modestly saturable. In a multiple-dose, dose-ranging study in healthy older adults administered doses ranging from 267 mg to 1,335 mg three times a day, the mean clearance decreased by approximately 25% above a dose of 801 mg three times a day. Following single dose administration of pirfenidone in healthy older adults, the mean apparent terminal elimination half-life was approximately 2.4 hours. Approximately 80% of an orally administered dose of pirfenidone is cleared in the urine within 24 hours of dosing. The majority of pirfenidone is excreted as the 5-carboxy-pirfenidone metabolite (&gt;95% of that recovered), with less than 1% of pirfenidone excreted unchanged in urine.</p><p><u>Special populations</u></p><p><em>Hepatic impairment</em></p><p>The pharmacokinetics of pirfenidone and the 5-carboxy-pirfenidone metabolite were compared in subjects with moderate hepatic impairment (Child-Pugh Class B) and in subjects with normal hepatic function. Results showed that there was a mean increase of 60% in pirfenidone exposure after a single dose of 801 mg pirfenidone (3 x 267 mg capsule) in patients with moderate hepatic impairment. Pirfenidone should be used with caution in patients with mild to moderate hepatic impairment and patients should be monitored closely for signs of toxicity especially if they are concomitantly taking a known CYP1A2 inhibitor (see sections 4.2 and 4.4). Pirfenidone is contraindicated in severe hepatic impairment and end stage liver disease (see sections 4.2 and 4.3).</p><p><em>Renal impairment</em></p><p>No clinically relevant differences in the pharmacokinetics of pirfenidone were observed in subjects with mild to severe renal impairment compared with subjects with normal renal function. The parent substance is predominantly metabolised to 5-carboxy-pirfenidone. The mean (SD) AUC0-&infin; of 5-carboxy-pirfenidone was significantly higher in the moderate (p = 0.009) and severe (p &lt; 0.0001) renal impairment groups than in the group with normal renal function; 100 (26.3) mg&bull;h/L and 168 (67.4) mg&bull;h/L compared to 28.7 (4.99) mg&bull;h/L respectively.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Renal</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Impairment Group</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Statistics</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>AUC</strong><strong>0-&infin; </strong><strong>(mg&bull;hr/L)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Pirfenidone</strong></p></td><td style="vertical-align:top"><p><strong>5-Carboxy-Pirfenidone</strong></p></td></tr><tr><td style="vertical-align:top"><p>Normal n=6</p></td><td style="vertical-align:top"><p>Mean (SD)</p><p>Median (25<sup>th</sup>-75<sup>th</sup>)</p></td><td style="vertical-align:top"><p>42.6 (17.9)</p><p>42.0 (33.1-55.6)</p></td><td style="vertical-align:top"><p>28.7 (4.99)</p><p>30.8 (24.1-32.1)</p></td></tr><tr><td style="vertical-align:top"><p>Mild n=6</p></td><td style="vertical-align:top"><p>Mean (SD)</p><p>Median (25<sup>th</sup>-75<sup>th</sup>)</p></td><td style="vertical-align:top"><p>59.1 (21.5)</p><p>51.6 (43.7-80.3)</p></td><td style="vertical-align:top"><p>49.3<sup>a</sup> (14.6)</p><p>43.0 (38.8-56.8)</p></td></tr><tr><td style="vertical-align:top"><p>Moderate n=6</p></td><td style="vertical-align:top"><p>Mean (SD)</p><p>Median (25<sup>th</sup>-75<sup>th</sup>)</p></td><td style="vertical-align:top"><p>63.5 (19.5)</p><p>66.7 (47.7-76.7)</p></td><td style="vertical-align:top"><p>100<sup>b</sup> (26.3)</p><p>96.3 (75.2-123)</p></td></tr><tr><td style="vertical-align:top"><p>Severe n=6</p></td><td style="vertical-align:top"><p>Mean (SD) Median (25<sup>th</sup>-75<sup>th</sup>)</p></td><td style="vertical-align:top"><p>46.7 (10.9)</p><p>49.4 (40.7-55.8)</p></td><td style="vertical-align:top"><p>168<sup>c</sup> (67.4)</p><p>150 (123-248)</p></td></tr></tbody></table><p>&nbsp;</p><p>AUC0-&infin; = area under the concentration-time curve from time zero to infinity.</p><p><sup>a</sup> p-value versus Normal = 1.00 (pair-wise comparison with Bonferroni)</p><p><sup>b</sup> p-value versus Normal = 0.009 (pair-wise comparison with Bonferroni)</p><p><sup>c</sup> p-value versus Normal &lt; 0.0001 (pair-wise comparison with Bonferroni)</p><p>Exposure to 5-carboxy-pirfenidone increases 3.5 fold or more in patients with moderate renal impairment. Clinically relevant pharmacodynamic activity of the metabolite in patients with moderate renal impairment cannot be excluded. No dose adjustment is required in patients with mild renal impairment who are receiving pirfenidone. Pirfenidone should be used with caution in patients with moderate renal impairment. The use of pirfenidone is contraindicated in patients with severe renal impairment (CrCl &lt;30ml/min) or end stage renal disease requiring dialysis (see sections 4.2 and 4.3).</p><p>Population pharmacokinetic analyses from 4 studies in healthy subjects or subjects with renal impairment and one study in patients with IPF showed no clinically relevant effect of age, gender or body size on the pharmacokinetics of pirfenidone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential.</p><p>In repeated dose toxicity studies increases in liver weight were observed in mice, rats and dogs; this was often accompanied by hepatic centrilobular hypertrophy. Reversibility was observed after cessation of treatment. An increased incidence of liver tumours was observed in carcinogenicity studies conducted in rats and mice. These hepatic findings are consistent with an induction of hepatic microsomal enzymes, an effect which has not been observed in patients receiving Pirfenidone. These findings are not considered relevant to humans.</p><p>A statistically significant increase in uterine tumours was observed in female rats administered 1,500 mg/kg/day, 37 times the human dose of 2,403 mg/day. The results of mechanistic studies indicate that the occurrence of uterine tumours is probably related to a chronic dopamine-mediated sex hormone imbalance involving a species specific endocrine mechanism in the rat which is not present in humans.</p><p>Reproductive toxicology studies demonstrated no adverse effects on male and female fertility or postnatal development of offspring in rats and there was no evidence of teratogenicity in rats (1,000 mg/kg/day) or rabbits (300 mg/kg/day). In animals placental transfer of pirfenidone and/or its metabolites occurs with the potential for accumulation of pirfenidone and/or its metabolites in amniotic fluid. At high doses (&ge;450 mg/kg/day) rats exhibited a prolongation of oestrous cycle and a high incidence of irregular cycles. At high doses (&ge;1,000 mg/kg/day) rats exhibited a prolongation of gestation and reduction in fetal viability. Studies in lactating rats indicate that pirfenidone and/or its metabolites are excreted in milk with the potential for accumulation of pirfenidone and/or its metabolites in milk.</p><p>Pirfenidone showed no indication of mutagenic or genotoxic activity in a standard battery of tests and when tested under UV exposure was not mutagenic. When tested under UV exposure pirfenidone was positive in a photoclastogenic assay in Chinese hamster lung cells.</p><p>Phototoxicity and irritation were noted in guinea pigs after oral administration of pirfenidone and with exposure to UVA/UVB light. The severity of phototoxic lesions was minimised by application of sunscreen.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Intra granular portion</u> Microcrystalline Cellulose Croscarmellose sodium</p><p><u>Binder</u></p><p>Hydroxypropyl Cellulose</p><p><u>Extra granular portion</u> Colloidal Silicon Dioxide Magnesium Stearate</p><p>&nbsp;</p><p><u>Film coat</u> Polyvinyl Alcohol Titanium Dioxide Macrogol</p><p>Talc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months (2 years)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fenido tablets are packed in PVC/Aclar Blister pack.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tadawi Biomedical Company, Tadawi Biomedical-KSA Riyadh, Sudair Industrial Area, Zone A, Road 11, Factory 107, Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                07/2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>